Dysfunctional microglia and tau pathology in Alzheimer's disease

Gunel Ayyubova1

  • 1Department of Cytology, Embryology and Histology, Azerbaijan Medical University, S. Vurgun Street, Baku 1102, Azerbaijan.

Insights

Chronic immune stimulation and malfunctioning microglia worsen neurodegeneration in Alzheimer's disease (AD) and tauopathies. Microglial dysfunction drives tau pathology spread, highlighting targets for AD treatments.

Area of Science:

  • Neuroscience
  • Immunology
  • Pathology

Background:

  • Chronic immune stimulation, involving microglia and inflammasome activation, exacerbates neurodegeneration in Alzheimer's disease (AD) and tauopathies.
  • Abnormalities in tau, amyloid-beta (Aβ), and microglial activation are hallmarks of dementia, suggesting their concerted role in cognitive impairment.
  • While Aβ aggregates are found in healthy individuals, tau pathology correlates more strongly with neurodegeneration and cognitive decline.

Purpose of the Study:

  • To review recent findings on the role of microglial cells in the development and progression of tau pathology.
  • To discuss the pathogenic mechanisms linking neuroinflammation and tau spread.
  • To identify potential therapeutic targets for AD based on these interactions.

Main Methods:

  • Literature review of human studies and animal models.
  • Analysis of postmortem brain studies and investigations on tau and amyloid pathology.
  • Examination of microglial functions, including phagocytosis and neuroprotection.

Main Results:

  • Malfunctioning microglia exhibit impaired clearance of amyloid plaques and correlate with tau tangle spread.
  • Hyperphosphorylated tau detaches from microtubules, leading to axonal deficits and neurofibrillary tangles (NFTs).
  • Microglial dysfunction is critical in driving tau pathology propagation.

Conclusions:

  • Microglial cells play a critical role in the pathogenesis and spread of tau pathology in AD and other tauopathies.
  • Understanding the interplay between neuroinflammation and tau spread is crucial for developing effective AD treatments.
  • Targeting microglial pathways offers a promising therapeutic strategy for tauopathies.

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
626
Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
9.7K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
246